Welcome to the Monthly QPS Preclinical Newsletter

Download the white paper to discover the importance of protein binding studies in drug development, explore the wide range of QPS toxicology capabilities, and catch up on the latest breakthroughs and insights on the QPS blog.

Greetings!

DMPK Protein Binding

At QPS, our bioanalysis labs conduct comprehensive protein binding studies to provide crucial insights into how drugs interact with proteins in biological samples. These studies are essential for:

Pharmacokinetic Understanding
Efficacy and Bioavailability
Drug-Drug Interactions
Safety and Toxicology
Optimization of Formulations
Predicting In Vivo Behavior
Dose Adjustment and Therapeutic Monitoring
Regulatory Requirements
Understanding Variability

Partner with QPS to leverage our expertise in protein binding studies and optimize your drug development process.

Download the White Paper

Plasma Protein Binding

Toxicology

At QPS, we offer a wide range of toxicology studies and preclinical safety tests essential for drug development. Our globally recognized toxicology scientists ensure quality and flexibility in designing specialized in vivo studies. Key services include:

General Toxicology
Genetic Toxicology
Specialized Studies
Regulatory Compliance

Explore the QPS brochure

A Flexible Approach to Toxicology

With over 30 years of experience, QPS has successfully completed many studies, providing high-quality data and reliable results. Partner with us to advance your drug development process efficiently and effectively.

Time is of the essence in drug development.

Contact QPS Today

Discover the Future of Science on the QPS Blog

Encouraging Preclinical Results Show Gene Therapy Reduces Seizures

California-based Capsida Biotherapeutics has reported promising preclinical results for CAP-002, its gene therapy for developmental and epileptic encephalopathy (DEE) caused by mutations in the syntaxin-binding protein 1 (STXBP1) gene...

Addressing a Devastating Disease

Read More QPS Blog Posts

Early Alzheimer’s Patients Benefit from Leqembi

Like many neurodegenerative diseases, early diagnosis and treatment of Alzheimer’s disease (AD) can greatly improve quality of life for individuals with the disease. Now, thanks to recent research into a drug called lecanemab-irmb, early Alzheimer’s patients have...

More Promising Options than Ever Before

Explore the Ultimate Guide to Gene Therapy

Subscribe to the QPS Blog

Visit our website www.qps.com

or contact us at info@qps.com

for an appointment.

www.qps.com | info@qps.com | +1 512 350 2827

We use your email address exclusively for sending QPS newsletters with a special e-mail program. If you no longer wish to receive any mailings, simply use the "unsubscribe" link at the bottom. If you don't unsubscribe, we assume that this consent also applies to the system of the GDPR. (Data protection notice: According to Art. 7 GDPR, the consent can of course also be withdrawn at any time after May 25, 2018.)